IWMF & Affiliate Publications

Downloadable Publications

IWMF, volunteers from the IWMF Affiliates, and WM researchers develop publications including Booklets, Treatment Guides, and Facts Sheets to provide the newly diagnosed and veteran patients, as well as their caregivers, with up-to-date information about Waldenstrom’s macroglobulinemia and how to treat it.

The IWMF does not warranty the content of these publications. We are making these available to you as information, and we encourage you to discuss what may be appropriate to you with your hematologist/oncologist.

Booklets

All languages

All languages
English Traditional Chinese 繁體中文 Simplified Chinese 简体中文 Espanol Francais Italiano French Deutsch Polskie Portuguesa Finnish Suomi
Basic Immunology

By Guy Sherwood, M.D., 2014
Revised Linda Nelson, 2018

Basic Immunology Booklet Cover

A comprehensive review of immunology and genetics as it relates to WM.

Frequently Asked Questions

By Peter DeNardis, Marcia Klepac, Elena Malunis, and Linda Nelson, 2017.
Revised Linda Nelson, 2019

This booklet answers frequently asked questions about WM in a very readable format for those who may not have a strong background in biology.

Glossary and Abbreviations

Written & compiled by Guy Sherwood, M.D., Bret Blakeslee, Sue Herms, & Peter DeNardis, 2015.
Revised Linda Nelson, Glenn Cantor, & Sue Herms, 2020.

This glossary is designed to help patients with WM learn and understand pertinent medical terms that relate to our disease.

Download
Medical Tests

By Guy Sherwood, M.D., 2007
Revised by Linda Nelson and Sue Herms, 2016, 2020

A reference booklet of medical terms and tests, this revision places particular emphasis on expanding the explanation of the Complete Blood Count and on Immunoglobulins. Tests for beta-2 microglobulin and light chains have been added, as has genetics testing.

Questions and Answers

By Guy Sherwood and Sue Herms, Revised 2010, 2014.
Revised Sue Herms and Linda Nelson, 2017.

Designed to provide detailed answers to questions about Waldenstrom’s macroglobulinemia, including a full glossary of terms.

Clinical Practice Guide for the Treatment of WM (Australia)

By Dipti Talaulikar, M.D., Constantine Tam, M.D., et al, 2016

This booklet is a consensus established by the Australian Medical Scientific Advisory Group, which consists of a panel of haematologists across Australia, and it is provided by  the IWMF Affiliate (WMozzies) in Australia.

Download
Guide to WM (Germany)

By Christian Buske, M.D., and George Hess, M.D., 2014
Revised 2019

This booklet is provided by the IWMF-Affiliate Morbus Waldenstrom (MOWA) in Germany.

Download
Guide to WM and LPL (UK)

By Shirley D’Sa, M.D., 2014, updated 2018, updated 2020.

This booklet is provided by the IWMF Affiliate Waldenstrom’s UK (WMUK). The drugs mentioned in the booklet are noted by their generic names and by their UK-specific trade names and may/may not be available in UK/US (or elsewhere) unless in the context of a clinical trial.

Download
Treatment Options Guides

All languages

All languages
English Traditional Chinese 繁體中文 Simplified Chinese 简体中文 Deutsch Espanol Francais Italiano

These Treatment Options Guides review drug therapies and treatment guidelines currently used in the management of Waldenstrom’s macroglobulinemia. They are designed to provide patients with some of the necessary information to allow them to participate with their physicians in determining the best course of treatment for their disease.

Alkylating Agents and Nucleoside Analogs

By Suzanne Herms, 2016
Revised 2019

This Guide discusses alkylating agents, such as chlorambucil (Leukeran), cyclophosphamide (Cytoxan), melphalan (Alkeran) and bendamustine (Bendeka, Treanda, Levact), as well as nucleoside analogs, such as fludarabine (Fludara) and cladribine (2CdA or Leustatin).

Monoclonal Antibodies

By Suzanne Herms, 2016
Revised 2019

This Guide discusses monoclonal antibodies, such as rituximab (Rituxan or Mabthera), ofatumumab (Arzerra), and alemtuzumab (Campath).

Proteasome Inhibitors

By Suzanne Herms, 2016
Revised 2019

This Guide includes proteasome inhibitors, such as bortezomib (Velcade), carfilzomib (Kyprolis), and ixazomib (Ninlaro).

Targeted Therapies/Pathway Inhibitors

By Suzanne Herms, 2016
Revised 2019

This Guide discusses targeted therapies/pathway inhibitors to B-cell signaling, such as ibrutinib (Imbruvica) and everolimus (RAD001 or Afinitor).

Fact Sheets

All languages

All languages
English Traditional Chinese 繁體中文 Simplified Chinese 简体中文 Deutsch Espanol Francais Italiano Norsk Polskie Portuguesa Finnish Suomi

These are short summaries that include information about WM, common treatments, and other associated topics.

Decoding Drug Names
Download
Human Intravenous Immunoglobulin (IVIG) Replacement Therapy
Ixazomib
Download
Specialty Pharmacy
Download
Share This